Risk factors of multidrug-resistant tuberculosis in China: A meta-analysis

doi:10.3969/j.issn.1000-6621.2019.12.011

Abstract

Abstract:

Objective This study systematically evaluated the risk factors for multidrug-resistant tuberculosis (MDR-TB) in China, which could provide an effective prevention and control strategy, and achieve the purpose of cause prevention (primary prevention).Methods The articles related to the risk factors of MDR-TB which published from January, 2005 to May, 2019 were searched in English databases (PubMed, Embase, Web of Science, Cochrane Library) and Chinese databases (China National Knowledge Internet, Wanfang, SinoMed and VIP database), and then meta-analysis was performed following the screening, extracting data and quality evaluation of the articles.Results According to the search results and inclusion and exclusion criteria, a total of 55 articles were included, and 9 risk factors related to MDR-TB were found by meta-analysis. The results showed that the migrant population (OR=1.92; 95%CI=1.48-2.51), low household income (OR=2.12; 95%CI=1.72-2.63), re-treatment (OR=6.28; 95%CI=4.72-8.36), anti-tuberculosis treatment history (OR=5.73; 95%CI=4.56-7.20), anti-tuberculosis treatment history ≥2 times (OR=4.41; 95%CI=3.35-5.80), adverse drug reactions (OR=4.89; 95%CI=2.48-9.62), treatment interruption (OR=3.59; 95%CI=2.02-6.38), lung cavity (OR=1.56; 95%CI=1.25-1.93) and smoking (OR=1.59; 95%CI=1.12-2.25) were closely related to the pathogenesis of MDR-TB.Conclusion The risk factors for MDR-TB in China are possibly migrant population, low household income, re-treatment, anti-tuberculosis treatment history, anti-tuberculosis treatment history ≥2 times, adverse reactions, treatment interruption, lung cavities and smoking.

Key words: China, Tuberculosis,multidrug-resistant, Risk factors, Meta-analysis as topic

Jin-hong XU,Song YANG,Li-xin ZHANG,Ying ZHONG,Qian QIU. Risk factors of multidrug-resistant tuberculosis in China: A meta-analysis[J]. Chinese Journal of Antituberculosis, 2019, 41(12): 1301-1309. doi: 10.3969/j.issn.1000-6621.2019.12.011

Figures/Tables 13

作者	发表年份	MDR-TB (例)	非MDR-TB (例)	纳入因素	NOS评分
Yang 等^[2]	2018	176	2797	与结核病患者接触史、药物治疗次数	6
徐莉娟和刘华^[3]	2018	22	298	抗结核药物治疗史	6
杨安文等^[4]	2018	1888	7969	性别、户籍、抗结核药物治疗史	6
Sun等^[5]	2017	227	225	药物治疗次数	7
Tan等^[6]	2017	74	95	户籍、家庭经济状况、与结核病患者接触史、吸烟	7
Peng等^[7]	2017	991	11211	药物治疗次数	6
Lv等^[8]	2017	359	3118	抗结核药物治疗史	6
Wu 等^[9]	2017	47	889	性别、抗结核药物治疗史	7
Li 等^[10]	2016	325	613	抗结核药物治疗史、肺部空洞	6
余述凤等^[11]	2016	83	98	户籍、家庭经济状况、药物治疗次数、不良反应、中断治疗、肺部空洞、吸烟	6
Huai等^[12]	2016	186	171	性别、户籍、家庭经济状况	8
Zhang等^[13]	2016	287	291	性别、抗结核药物治疗史、与结核病患者接触史、吸烟	7
陈森林等^[14]	2016	163	329	性别、药物治疗次数、与结核病患者接触史、不良反应、中断治疗、吸烟	5
高春景等^[15]	2016	105	718	性别、户籍	6
汪清雅等^[16]	2016	67	67	与结核病患者接触史	9
刘慧梅等^[17]	2016	60	120	不良反应、中断治疗、肺部空洞、吸烟	8
周群博等^[18]	2016	280	4991	性别、户籍	6
Zhao 等^[19]	2015	38	230	性别、户籍、肺部空洞、与结核病患者接触史	6
韩珍等^[20]	2015	130	110	户籍	6
刘荣梅等^[21]	2015	70	199	吸烟	5
朱倬敏^[22]	2015	120	120	户籍、抗结核药物治疗史、中断治疗	8
韦余东等^[23]	2015	99	73	不良反应、吸烟	8
作者	发表年份	MDR-TB (例)	非MDR-TB (例)	纳入因素		NOS评分
宋其生等^[24]	2015	104	606	药物治疗次数、肺部空洞		5
刘泓等^[25]	2015	20	188	性别、户籍、吸烟		5
高会霞等^[26]	2015	52	249	中断治疗、吸烟		6
李莉等^[27]	2015	253	3361	性别		5
魏淑贞等^[28]	2015	45	178	性别、药物治疗次数		5
Yang 等^[29]	2015	138	280	户籍、吸烟		6
Jiao 等^[30]	2015	22	45	性别、抗结核药物治疗史、与结核病患者接触史		6
Li 等^[31]	2015	110	110	户籍		7
赵锦明等^[32]	2014	51	235	性别、户籍、药物治疗次数		6
Wang 等^[33]	2014	61	50	户籍、不良反应、吸烟		7
黄曙海等^[34]	2013	68	359	性别、户籍、药物治疗次数		5
Chen 等^[35]	2013	98	83	性别、户籍、肺部空洞、不良反应		8
Liu等^[36]	2013	88	924	性别、户籍、抗结核药物治疗史		5
Chien 等^[37]	2013	178	1912	性别、肺部空洞		5
Wang 等^[38]	2013	175	2009	性别、药物治疗次数		5
张玉等^[39]	2013	345	345	户籍、抗结核药物治疗史、与结核病患者接触史、中断治疗		8
邵燕等^[40]	2013	34	226	性别、户籍		6
陆伟等^[41]	2013	117	643	户籍、抗结核药物治疗史		6
Liang等^[42]	2012	241	1754	性别、抗结核药物治疗史、肺部空洞		5
徐吉英等^[43]	2012	23	264	性别、与结核病患者接触史、中断治疗		5
陈亮等^[44]	2012	377	433	性别、户籍、中断治疗		5
宁柱等^[45]	2012	25	209	性别、药物治疗次数		5
Shao等^[46]	2011	303	1521	性别、抗结核药物治疗史、吸烟		6
Wang等^[47]	2011	41	477	抗结核药物治疗史		5
吴兰香^[48]	2011	87	87	肺部空洞、与结核病患者接触史		7
王海东等^[49]	2011	241	1754	性别、药物治疗次数		6
He 等^[50]	2011	100	97	性别、肺部空洞、与结核病患者接触史		5
许丽等^[51]	2010	39	626	户籍		5
Shen 等^[52]	2009	333	7018	性别、户籍、抗结核药物治疗史、肺部空洞		5
王介营等^[53]	2009	25	402	肺部空洞		7
朱建福等^[54]	2009	13	82	性别、抗结核药物治疗史、与结核病患者接触史		5
Law 等^[55]	2008	156	322	户籍		7
陆兰英等^[56]	2005	100	200	抗结核药物治疗史		7

References 61

[1]	World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019.
[2]	Yang Z, Zhou C, Ning Z , et al. High-risk screening and detection of multidrug-resistant tuberculosis in two prefectures of China: a drug susceptibility surveillance-based secondary data analysis. Glob Health Action, 2018,11(1):1500763.
[3]	徐莉娟, 刘华 . 肺结核耐药情况及影响因素分析. 传染病信息, 2018,31(3):72-74.
[4]	杨安文, 周亮, 徐祖辉 , 等. 湖南省肺结核四种一线抗结核药物耐药特征及影响因素研究. 中国人兽共患病学报, 2018,34(5):396-403.
[5]	Sun ET, Xia D, Li BH , et al. Association of Immune Factors with Drug-Resistant Tuberculosis: A Case-Control Study. Med Sci Monit, 2017,23:5330-5336.
[6]	Tan D, Wang B, Li X , et al. Identification of Risk Factors of Multidrug-Resistant Tuberculosis by using Classification Tree Method. Am J Trop Med Hyg, 2017,97(6):1720-1725.
[7]	Peng Y, Chen SH, Zhang L , et al. Multidrug-resistant Tuberculosis Burden among the New Tuberculosis Patients in Zhejiang Province: An Observational Study, 2009-2013. Chin Med J (Engl), 2017,130(17):2021-2026.
[8]	Lv XT, Lu XW, Shi XY , et al. Prevalence and risk factors of multi-drug resistant tuberculosis in Dalian, China. J Int Med Res, 2017,45(6):1779-1786.
[9]	Wu B, Zhang L, Liu Z , et al. Drug-resistant tuberculosis in Zhejiang Province, China: an updated analysis of time trends, 1999-2013. Glob Health Action, 2017,10(1):1293925.
[10]	Li D, Wang JL, Ji BY , et al. Persistently high prevalence of primary resistance and multidrug resistance of tuberculosis in Heilongjiang Province, China. BMC Infect Dis, 2016,16(1):516.
[11]	余述凤, 梅晓冬, 阚晓宏 , 等. 安徽省耐多药肺结核危险因素病例对照研究. 中华疾病控制杂志, 2016,20(10):1026-1028.
[12]	Huai P, Huang X, Cheng J , et al. Proportions and Risk Factors of Developing Multidrug Resistance Among Patients with Tuberculosis in China: A Population-Based Case-Control Study. Microb Drug Resist, 2016,22(8):717-726.
[13]	Zhang C, Wang Y, Shi G , et al. Determinants of multidrug-resistant tuberculosis in Henan province in China: a case control study. BMC Public Health, 2016,16(1):42.
[14]	陈森林, 杨尚鹏, 龚伟 , 等. 肺结核患者产生耐多药危险因素的研究. 中国防痨杂志, 2016,38(1):47-52. doi: 10.3969/j.issn.1000-6621.2016.01.011 URL
[15]	高春景, 刘加彬, 张瑞梅 , 等. 耐多药肺结核产生的危险因素分析. 江苏医药, 2016,42(16):1776-1778.
[16]	汪清雅, 胡代玉, 刘英 , 等. 重庆市万州片区耐多药肺结核危险因素1:1病例对照Logistic回归分析. 重庆医学, 2016,45(11):1553-1556.
[17]	刘慧梅, 张瑞梅, 刘加彬 , 等. 1∶2个体匹配青年肺结核患者耐多药临床危险因素分析. 山西医科大学学报, 2016,47(9):834-836.
[18]	周群博, 陆林, 许琳 , 等. 云南省涂阳耐多药肺结核患者特征及影响因素分析. 现代预防医学, 2016,43(21):3983-3985, 3992.
[19]	Zhao JN, Zhang XX, He XC , et al. Multidrug-Resistant Tuberculosis in Patients with Chronic Obstructive Pulmonary Disease in China. PLoS One, 2015,10(8):e0135205.
[20]	韩珍, 李晓芬, 冷雪 . 复治肺结核患者耐多药的影响因素分析. 国际检验医学杂志, 2015,36(11):1568-1570.
[21]	刘荣梅, 王玉清, 高孟秋 , 等. 青海省耐多药肺结核病危险因素的病例对照研究. 临床肺科杂志, 2015,20(4):592-595.
[22]	朱倬敏 . 许昌市120例耐多药结核病的危险因素分析. 实用心脑肺血管病杂志, 2015,23(5):82-84.
[23]	韦余东, 陈松华, 彭颖 , 等. 复治肺结核发生耐多药危险因素的病例-病例对照研究. 浙江预防医学, 2015,27(2):124-126, 130.
[24]	宋其生, 蔡春葵, 任彦薇 , 等. 大连市耐多药结核危险因素分析. 大连医科大学学报, 2015,37(1):45-48.
[25]	刘泓, 刘金宝, 芮宝玲 , 等. 乌鲁木齐市耐多药肺结核病患者危险因素分析. 疾病预防控制通报, 2015,30(2):20-22.
[26]	高会霞, 侯军良, 张志 , 等. 346例肺结核患者结核分枝杆菌耐药性调查及耐多药结核病影响因素分析. 中国防痨杂志, 2015,37(11):1130-1135.
[27]	李莉, 孙建胜, 张海清 , 等. 徐州市耐多药结核病流行病学特征及危险因素分析. 江苏预防医学, 2015,26(4):60-61.
[28]	魏淑贞, 梁庆福, 林淑芳 , 等. 福建省复治肺结核患者耐药现况与其影响因素分析. 现代预防医学, 2015,42(16):3008-3011, 3015.
[29]	Yang X, Yuan Y, Pang Y , et al. The burden of MDR/XDR tuberculosis in coastal plains population of China. PLoS One, 2015,10(2):e0117361.
[30]	Jiao WW, Liu ZG, Han R , et al. Prevalence of drug resistant Mycobacterium tuberculosis among children in China. Tuberculosis (Edinb), 2015,95(3):315-320.
[31]	Li XX, Lu W, Zu RQ , et al. Comparing risk factors for primary multidrug-resistant tuberculosis and primary drug-susceptible tuberculosis in Jiangsu province, China: a matched-pairs case-control study. Am J Trop Med Hyg, 2015,92(2):280-285.
[32]	赵锦明, 黄曙海, 刘飞鹰 , 等. 复治涂阳肺结核患者耐药危险因素探讨. 现代预防医学, 2014,41(17):3211-3214, 3220.
[33]	Wang K, Chen S, Wang X , et al. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China. Microb Drug Resist, 2014,20(4):294-300.
[34]	黄曙海, 蓝如束, 刘飞鹰 , 等. 广西壮族自治区肺结核耐药性调查及复治患者耐药相关因素分析. 中国防痨杂志, 2013,35(9):711-717.
[35]	Chen S, Huai P, Wang X , et al. Risk factors for multidrug resistance among previously treated patients with tuberculosis in eastern China: a case-control study. Int J Infect Dis, 2013,17(12):e1116-1120.
[36]	Liu Q, Zhu L, Shao Y , et al. Rates and risk factors for drug resistance tuberculosis in Northeastern China. BMC Public Health, 2013,13(1):1171.
[37]	Chien JY, Lai CC, Tan CK , et al. Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan. J Antimicrob Chemother, 2013,68(8):1910-1916.
[38]	Wang SF, Zhou Y, Pang Y , et al. Prevalence and Risk Factors of Primary Drug-Resistant Tuberculosis in China. Biomed Environ Sci, 2016,29(2):91-98.
[39]	张玉, 侯双翼, 杨成凤 , 等. 耐多药结核病危险因素logistic回归分析. 中国卫生统计, 2013,30(2):190-191, 195.
[40]	邵燕, 宋红焕, 李国莉 , 等. 江苏省2010年结核病耐药流行病学调查. 南京医科大学学报(自然科学版), 2013,33(2):282-285, 290.
[41]	陆伟, 周扬, 陈诚 , 等. 江苏省社区人群结核杆菌耐药状况及影响因素研究. 中华疾病控制杂志, 2013,17(7):560-563.
[42]	Liang L, Wu Q, Gao L , et al. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax, 2012,67(7):632-638.
[43]	徐吉英, K.DeRiemer, 李辉 , 等. 河南省5县市2007年耐药结核病及危险因素研究. 现代预防医学, 2012,39(2):273-277, 280.
[44]	陈亮, 周琳, 尹建军 , 等. 耐多药结核病的筛查效果及危险因素分析. 结核病与肺部健康杂志, 2012,1(2):101-104.
[45]	宁柱, 邓建平, 李群 , 等. 四川省自贡市2010—2011年耐药结核病社会人口学和临床影响因素研究. 结核病与肺部健康杂志, 2012,1(2):113-117.
[46]	Shao Y, Yang D, Xu W , et al. Epidemiology of anti-tuberculosis drug resistance in a Chinese population: current situation and challenges ahead. BMC Public Health, 2011,11(1):110.
[47]	Wang W, Wang J, Zhao Q , et al. Contribution of rural-tour-ban migration in the prevalence of drug resistant tuberculosis in China. Eur J Clin Microbiol Infect Dis, 2011,30(4):581-586.
[48]	吴兰香 . 耐多药结核病人影响因素病例对照研究. 中国公共卫生, 2011,27(4):401-402. doi: 10.11847/zgggws2011-27-04-09 URL
[49]	王海东, 谢艳光, 闫兴录 , 等. 耐多药肺结核相关因素探讨. 中国防痨杂志, 2011,33(2):109-112.
[50]	He GX, Wang HY, Borgdorff MW , et al. Multidrug-resistant tuberculosis, People’s Republic of China, 2007—2009. Emerg Infect Dis, 2011,17(10):1831-1838.
[51]	许丽, 杨应周, 吕德良 , 等. 深圳市结核病耐药情况及影响因素分析. 中国热带医学, 2010,10(11):1333-1335.
[52]	Shen X, DeRiemer K, Yuan ZA , et al. Drug-resistant tuberculosis in Shanghai, China, 2000—2006: prevalence, trends and risk factors. Int J Tuberc Lung Dis, 2009,13(2):253-259.
[53]	王介营, 张道全, 王洪辉 . 滨州市流动人口的结核病耐药状况及相关因素分析. 临床肺科杂志, 2011,16(3):407-409.
[54]	朱建福, 王伟炳, 王学才 , 等. 德清县耐药肺结核流行情况及危险因素研究. 浙江预防医学, 2009,21(9):6-8.
[55]	Law WS, Yew WW, Chiu Leung C , et al. Risk factors for multidrug-resistant tuberculosis in Hong Kong. Int J Tuberc Lung Dis, 2008,12(9):1065-1070.
[56]	陆兰英, 王卫华, 曾庆志 , 等. 武汉地区耐多药结核病危险因素的病例对照研究. 中国防痨杂志, 2005,27(5):340-342.
[57]	Elmi OS, Hasan H, Abdullah S , et al. Multidrug-resistant tuberculosis and risk factors associated with its development: a retrospective study. J Infect Dev Ctries, 2015,9(10):1076-1085.
[58]	Rumende CM . Risk Factors for Multidrug-resistant Tuberculosis. Acta Med Indones, 2018,50(1):1-2.
[59]	Mulu W, Mekonnen D, Yimer M , et al. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State. Afr Health Sci, 2015,15(2):368-377.
[60]	Mondoni M, Fois A, Centanni S , et al. Could BAL Xpert ^® MTB/RIF replace transbronchial lung biopsy everywhere for suspected pulmonary TB patients? Int J Tuberc Lung Dis, 2016,20(8):1135.
[61]	Pradipta IS, Forsman LD, Bruchfeld J , et al. Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. J Infect, 2018,77(6):469-478.